Trulicity vs. Ozempic

Are Trulicity and Ozempic the same drug?

No — they are different molecules in the same drug class. Both Trulicity (dulaglutide) and Ozempic (semaglutide) are GLP-1 receptor agonists — they work through the same single hormone pathway — but they are made by different manufacturers and are not equally potent.

When the two were compared head-to-head, semaglutide lowered blood sugar and body weight more than dulaglutide [1], [2], [3]. Unlike the tirzepatide drugs (Mounjaro, Zepbound), neither of these acts on a second hormone; the difference here is potency, not mechanism.

What is Trulicity?

Trulicity (dulaglutide) is a once-weekly GLP-1 injection FDA-approved to improve blood sugar in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes who have heart disease or multiple cardiovascular risk factors. It is dosed from 0.75 mg up to 4.5 mg once weekly.

A defining feature is its device: a single-dose, ready-to-use autoinjector with the needle hidden and no dose to dial, which many people find easier — especially if they are needle-averse or have limited dexterity. Trulicity is not FDA-approved for weight loss, and dulaglutide has no separate weight-management brand [1], [4].

What is Ozempic?

Ozempic (semaglutide) is a once-weekly GLP-1 injection FDA-approved for type 2 diabetes, to reduce cardiovascular risk in type 2 diabetes with heart disease, and (as of 2025) to slow chronic kidney disease in type 2 diabetes. It is dosed from 0.25 mg up to 2 mg once weekly in a multi-dose pen.

Ozempic is widely used off-label for weight loss but is not FDA-approved for it — that is the role of its higher-dose sibling, Wegovy [2], [5], [6].

How they work

Both mimic GLP-1, a gut hormone that curbs appetite, slows stomach emptying, and prompts insulin when blood sugar is high [1], [2]. They are in the same class, so the type of effect is the same.

The reason Ozempic produces larger reductions in head-to-head testing comes down to the molecule and the doses studied — semaglutide is simply the more potent GLP-1 agonist of the two [3].

Effectiveness: blood sugar and weight

Semaglutide beat dulaglutide in the only trial that tested them head-to-head. In SUSTAIN-7, 1,201 adults with type 2 diabetes on metformin were randomized for 40 weeks.

At the higher doses, Ozempic (semaglutide 1 mg) lowered HbA1c by −1.8% and body weight by −6.5 kg, versus −1.4% and −3.0 kg for Trulicity (dulaglutide 1.5 mg); the lower-dose comparison favored semaglutide too (−1.5% / −4.6 kg vs −1.1% / −2.3 kg). All differences were statistically significant [3].

In short, Ozempic is the stronger drug for both blood-sugar control and weight — though Trulicity still produces meaningful improvement, and the simpler device leads some people and clinicians to prefer it [3], [4].

Stronger on paper isn't the whole story

Ozempic's head-to-head win is real, but it doesn't make Trulicity the wrong choice for everyone.

For many people the practical gap is smaller than the trial numbers suggest: both drugs lower A1c substantially, both are once weekly, and adherence — actually taking the medication consistently — often matters more than a fraction of a percentage point of HbA1c.

Trulicity's no-fuss autoinjector, individual tolerability, and especially insurance coverage frequently decide which drug a person does best on. The most effective GLP-1 is the one you can get, afford, and stick with.

Heart and kidney protection

Both protect the heart, to different degrees. In the REWIND trial, Trulicity reduced major cardiovascular events by 12% versus placebo — notable because the trial included many people without established heart disease [4]. In SUSTAIN-6, Ozempic reduced those events by 26% [5].

Ozempic also has an FDA-approved kidney indication, having reduced major kidney-disease events by 24% in the FLOW trial — something Trulicity does not carry [6]. For someone with diabetes plus kidney disease, that can tip the decision toward Ozempic.

What about weight loss?

Neither is FDA-approved for weight loss, though both cause some as a side effect of appetite reduction. Semaglutide produces more weight loss than dulaglutide, and semaglutide also has a dedicated weight-management version — Wegovy — dosed specifically for obesity. Dulaglutide has no such sibling.

If weight loss is the primary goal, that points toward the semaglutide family rather than Trulicity [2], [3].

What to expect: timeline

Neither drug works overnight. Both start at a low dose and step up over weeks to limit nausea, and blood-sugar and weight changes build over months. In the trials, the effects were measured at 40 weeks.

Both are long-term treatments for a chronic condition: stop them and blood sugar drifts back up and appetite returns, so they are meant to be taken and supervised over the long run [1], [2], [3].

Dosing & administration

Both are once-weekly subcutaneous injections started low and titrated up to limit nausea. Trulicity goes 0.75 → 1.5 → 3 → 4.5 mg, in a single-dose autoinjector with no needle handling or dose dialing. Ozempic goes 0.25 → 0.5 → 1 → 2 mg, in a multi-dose pen that requires attaching a needle and selecting the dose [1], [2].

Side effects & safety

Side effects are similar because both act on the GLP-1 pathway — predominantly gastrointestinal (nausea, diarrhea, vomiting, constipation), usually mild-to-moderate and worst just after starting or moving up a dose [1], [2].

Serious risks & boxed warning

Both carry a boxed warning for thyroid C-cell tumors and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 [1], [2]. Both can also cause pancreatitis, gallbladder disease, acute kidney injury (often from dehydration), and low blood sugar when combined with insulin or a sulfonylurea [1], [2].

Who should not take these (and key cautions)

Avoid either drug with a personal or family history of MTC or MEN 2, or a prior serious reaction to it [1], [2]. Use caution with a history of pancreatitis or gallbladder disease. Both should be used carefully in pregnancy — semaglutide in particular should be stopped at least 2 months before a planned pregnancy because it clears slowly [2].

Tell your clinician your full history before starting.

Cost & insurance coverage

Without insurance, both run roughly $900–$1,000 per month at list price [1], [2]. Because both are approved for type 2 diabetes, insurers more often cover them for that diagnosis. Which one your plan prefers — and the copay card available — usually matters more than the small difference in sticker price.

A supervised program can help navigate coverage and prior authorizations.

A note on compounded versions: compounded GLP-1 medications can be a lower-cost route, and the rules around them shifted as the recent shortages resolved [7]. Quality and physician oversight vary by source, so a compounded option should come from a licensed, supervised medical program using a reputable compounding pharmacy — not an anonymous online seller.

JumpstartMD prescribes and supervises these medications, including compounded options where appropriate.

Can you switch between them?

Yes — switching is common and is done under medical supervision. People often move from Trulicity to Ozempic for stronger blood-sugar or weight effect, or to Trulicity for the simpler device or coverage reasons. Because they are different molecules, a clinician restarts the dose ladder for the new drug rather than matching doses.

You should not take two GLP-1 drugs at the same time [1], [2].

Which is right for you?

• You want the strongest blood-sugar and weight effect → Ozempic won the head-to-head (SUSTAIN-7) [3].
• You have diabetes with kidney disease → Ozempic has the FDA-approved kidney indication (FLOW) [6].
• Ease of use or needle anxiety is the priority → Trulicity's hidden-needle, no-dialing autoinjector is the simpler device [1].
• Coverage is the obstacle → the answer often comes down to which one your plan will pay for.

The right choice depends on your diagnosis, other conditions, insurance, and comfort with the device — exactly what a supervised consultation sorts out. JumpstartMD physicians prescribe and manage both Trulicity and Ozempic, including dose titration and side-effect management.